- Home
- NVNI vs ITOS Comparison
NVNI vs ITOS Comparison
Compare NVNI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- ITOS
- Stock Information
- Founded
- NVNI 2019
- ITOS 2011
- Country
- NVNI Brazil
- ITOS United States
- Employees
- NVNI N/A
- ITOS N/A
- Industry
- NVNI
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVNI
- ITOS Health Care
- Exchange
- NVNI Nasdaq
- ITOS Nasdaq
- Market Cap
- NVNI 204.8M
- ITOS 272.5M
- IPO Year
- NVNI N/A
- ITOS 2020
- Fundamental
- Price
- NVNI $6.12
- ITOS $7.48
- Analyst Decision
- NVNI
- ITOS Strong Buy
- Analyst Count
- NVNI 0
- ITOS 3
- Target Price
- NVNI N/A
- ITOS $21.33
- AVG Volume (30 Days)
- NVNI 22.8M
- ITOS 268.0K
- Earning Date
- NVNI 02-11-2025
- ITOS 03-05-2025
- Dividend Yield
- NVNI N/A
- ITOS N/A
- EPS Growth
- NVNI N/A
- ITOS N/A
- EPS
- NVNI N/A
- ITOS N/A
- Revenue
- NVNI $23,558,620.00
- ITOS $35,000,000.00
- Revenue This Year
- NVNI $25.91
- ITOS $271.18
- Revenue Next Year
- NVNI $17.52
- ITOS N/A
- P/E Ratio
- NVNI N/A
- ITOS N/A
- Revenue Growth
- NVNI 38.59
- ITOS N/A
- 52 Week Low
- NVNI $0.33
- ITOS $7.09
- 52 Week High
- NVNI $12.19
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- NVNI 74.08
- ITOS 43.24
- Support Level
- NVNI $4.57
- ITOS $7.30
- Resistance Level
- NVNI $7.45
- ITOS $7.91
- Average True Range (ATR)
- NVNI 1.18
- ITOS 0.32
- MACD
- NVNI 0.45
- ITOS -0.02
- Stochastic Oscillator
- NVNI 88.08
- ITOS 17.82
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.